Request for Proposal
Status: RFP is Closed

Partner in the utilization of antibody intracellular activated drug conjugate (AiADC) technology

Request Number
Due Date
Jun 9
Program Manager


  • AiADC technology licensing
  • A supply of antibody-drug conjugates provided for Proposer to make technology assessment 


Details will be discussed separately based on proposals

How to  Apply
Click on "Respond", complete the form to the extent possible, and submit along with other attachment files available. 
After creating your account for NineSights, your draft will be automatically saved and you can resume later from "Control Center". Please note you do not submit confidential information at this process.
This request for proposals in PDF format is available here.

If you have any questions or request, please feel free to contact us at: 

RFP was closed on
Jun 2019

RFP Title


Partner in the utilization of antibody intracellular activated drug conjugate (AiADC) technology
RFP Description

NineSigma, representing Sumitomo Dainippon Pharma Co., Ltd. ( ) (the "Client"), seeks a partner that wishes to make use of (i.e. technology assessment / licensing-in) an antibody-drug conjugate (ADC) technology developed by the Client called antibody intracellular activated drug conjugate (AiADC) technology.

The Client aims to bring innovative anti-cancer drugs to the market by developing ADC technology that can be used generously for various antibodies. The Client has already succeeded in developing AiADC technology, which is more effective and safer than conventional ADC technologies. They believe that the innovative technology can make a new solution in cancer treatment. They seek to make the technology applicable to a wider range of antibodies.

With an aim to accelerate drug discovery based on its AiADC technology, the Client has decided to make this RFP to broaden the potential of this proprietary technology through partnership with a company that possesses promising antibody seeds.

Key Success Criteria

Potential partner

The Client looks for proposals from companies that develop antibodies for cancer treatment and wish to engage in either of the following:

  • In-house assessment of the Client's AiADC technology
  • Joint research/development with the Client 



Sumitomo Dainippon Presents Preclinical Key Data on AiADC technology at the AACR2019 Annual Meeting on March 31, 2019 1:00PM-5:00PM:

  • #1663: Antibody intracellular activated drug conjugate (AiADC) as novel ADC technology
  • Georgia World Congress Center (Atlanta, Georgia, USA), Exhibit Hall B, Poster Section 9 – Poster Board 14

The Client would like to discuss the detail with the candidates who will apply in this project at the AACR2019.


Overview and characteristics of the newly developed AiADC technology

  • Applicable to various antibodies
    The Client's AiADC technology can be applied to various antibodies and has shown high levels of in vitro activity in application to not only anti-CD30 antibodies but other antibodies such as anti-HER2 antibodies. This demonstrates the great versatility and high efficacy of the technology.The data when using AiADC for anti-CD30 antibody is described below.
  • A highly novel payload
    The payload on the Client's AiADC is a microtubule destabilizer, which has activity equal to or more potent than that of monomethyl auristatin E (MMAE).

  • May be used in combination with immunotherapy
    DSP payload is highly hydrophilic and has low cell membrane permeability, which means that the payload will not be delivered into cells on its own, and has no effect on anything other than the target cells (Figure 1, Table 1). Because the AiADC has little effect on immune cells, it may be used in combination with immunotherapy, which is intended to activate immune cells. 


Figure 1. Overview of AiADC technology
The specificity of the anti-CD30 antibody-drug conjugate created by the AiADC technology (anti-CD30 AiADC) depending on the expression of CD30 was analyzed. The results showed efficacy with high selectivity only to CD30 expressing cells. 

Table 1. Efficacy in CD30-positive cells (Karpas-299) and CD30-negative cells (SK-BR-3) 

  • High levels of efficacy
    Tumor-bearing mice were given a single dose of anti-CD30 AiADC created using the AiADC technology with a drug-to-antibody ratio (DAR) of 8, or anti-CD30 Vedotin created using conventional ADCs with an average DAR of 4. A comparison of changes in the tumor volume in the mice found that anti-CD30 AiADC showed high levels of antitumor activity.

    Figure 2. In vivo evaluation of drug efficacy in cell-derived tumor xenograft murine models
    (Left: Anti-CD30 AiADC created using AiADC technology; Right: anti-CD30 Vedotin based on conventional ADC)

  • High levels of safety and reduced adverse reactions
    The results of toxicity studies in rats confirmed a favorable safety profile for the anti-CD30 AiADC, which did not show toxicity even when given in a dose ten times higher than that of anti-CD30 Vedotin (created using conventional ADCs). 

Table 2. Toxicity studies in rats


  • Able to produce homogenous ADCs
    The Client's AiADC technology enables the ratio of antibody to drug to be kept constant, which makes it possible to produce homogenous ADCs. This makes it a beneficial technology from the GMP perspective, among others.
Items to be Submitted

Proposal shall have clear points and should not include confidential information. Supplemental files may be submitted in addition to the proposal.


The client will evaluate all responses with the following criteria.

  • Overall scientific and technical merit
  • Approach to proof of concept or performance
  • Economic potential of concept
  • Realism of the proposed plan (action items, timeline, roles, deliverables, cost estimation)
  • Potential for proprietary position
  • Respondents’ capability and related experiences


After the submission due date, the client will review all submitted proposals. NineSigma will send the review results to each proposer 6-8 weeks after the due date. The client possibly asks clarifying questions before selecting the most suitable candidates for collaboration. The client will select best candidates through evaluations. During the selection process, the client may execute NDA with selected respondents, seek further information disclosure, and discuss specific development targets or potential opportunities.
The client will execute necessary agreements with the selected respondents and move to the advanced development phase. Specifics of any collaboration will be determined through consultation with the concerned parties.

Preferred Collaboration Types
Area of Interest